Imunon, Inc.
IMNN · XNASCIK 749647fmd_0WBHVM5TB4KQJ9SV3VMJRKVWTRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 1 | 1 | 1 | 1 | 1 | 1 | – | – | – |
| Realized investment gains (losses) | – | – | – | – | – | – | – | (0) | 0 | – |
| Research and development | 15 | 13 | 12 | 13 | 11 | 11 | 12 | 11 | 12 | 8 |
| Total operating expenses | 21 | 19 | 22 | 21 | 19 | 22 | 25 | 21 | 19 | 15 |
| Operating income | (21) | (18) | (21) | (21) | (18) | (21) | (25) | (21) | (19) | (15) |
| Interest expense | 1 | 0 | 1 | 1 | 1 | 1 | 5 | 0 | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | – |
| Other non-operating income (expense) | (1) | (2) | (1) | 2 | (5) | (1) | (13) | 0 | 1 | 0 |
| Income before taxes | – | (20) | (22) | (19) | (23) | (22) | (37) | (21) | 19 | 15 |
| Income tax expense | – | – | (10) | (2) | (2) | (1) | (2) | (1) | – | – |
| Net income from continuing operations | – | – | (12) | (17) | (21) | (21) | (36) | (20) | – | – |
| Net income | (22) | (20) | (12) | (17) | (21) | (21) | (36) | (20) | (19) | (14) |
| Net income to common shareholders | (22) | (21) | (12) | – | – | – | – | – | – | – |